Posted by Michael Wonder on 16 Apr 2025
Merck’s Tepmetko wins reimbursement in Korea after 3.5 years, expanding access for lung cancer patients with rare MET mutation
15 April 2025 - Merck’s targeted lung cancer therapy Tepmetko (tepotinib) has finally secured reimbursement from the National Health Insurance Service, three years and six months after it was approved by the Ministry of Food and Drug Safety in November 2021.
The milestone opens the door for broader patient access to the first reimbursed MET exon 14 skipping mutation-targeting therapy in the country.
